Tanabe Pharma Corporation
167
0
2
157
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
4.8%
8 terminated/withdrawn out of 167 trials
95.2%
+8.6% vs industry average
48%
80 trials in Phase 3/4
66%
103 of 157 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (167)
Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS
Role: lead
PK Study in Subjects With Severe Hepatic Impairment
Role: lead
Exploratory Clinical Study of MT-2301
Role: lead
A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects
Role: lead
Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05)
Role: collaborator
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07)
Role: collaborator
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
Role: lead
An Exploratory Study of MT-2990 in Patients With AAV
Role: lead
An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes
Role: lead
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus
Role: lead
A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Role: lead
A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia
Role: lead
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
Role: lead
Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes
Role: lead
Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke
Role: lead
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment
Role: lead
A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
Role: lead
Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients
Role: lead
A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia
Role: lead
A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)
Role: lead